Tanezumab, a recombinant humanized mAb against nerve growth factor for the treatment of acute and chronic pain

Current Opinion in Molecular Therapeutics

Volumn 12, Issue 1, 2010, Pages 94-106

  Cattaneo, Antonino ^a,b  

^a EUROPEAN BRAIN RESEARCH INSTITUTE   (Italy)

^b SCUOLA NORMALE SUPERIORE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; FREUND ADJUVANT; INDOMETACIN; MONOCLONAL ANTIBODY; MORPHINE; MORPHINE SULFATE; MUMAB 911; NAPROXEN; NARCOTIC ANALGESIC AGENT; NERVE GROWTH FACTOR; NERVE GROWTH FACTOR ANTIBODY; NERVE GROWTH FACTOR RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; OXYCODONE; PLACEBO; PROTEIN TYROSINE KINASE A; TANEZUMAB; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANALGESIA; ARTHRALGIA; ARTHRITIS; BONE PAIN; CANCER PAIN; CHRONIC PAIN; CLINICAL TRIAL; COMPLEX REGIONAL PAIN SYNDROME TYPE I; DIARRHEA; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SPECIFICITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSESTHESIA; ENDOMETRIOSIS PAIN; FRACTURE PAIN; HUMAN; HYPERESTHESIA; INJECTION SITE PAIN; INJECTION SITE REACTION; KNEE PAIN; LACTATION; LOW BACK PAIN; MONOTHERAPY; MUSCLE CRAMP; OSTEALGIA; OSTEOARTHRITIC PAIN; PAIN; PARESTHESIA; PATIENT SATISFACTION; PERINATAL PERIOD; PERIPHERAL NEUROPATHY; POSTHERPETIC NEURALGIA; POSTOPERATIVE PAIN; PREGNANCY; REVIEW; SENSORY DYSFUNCTION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; UPPER RESPIRATORY TRACT INFECTION;

ANTIBODIES, MONOCLONAL; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; HUMANS; INFLAMMATION; NERVE GROWTH FACTOR; PAIN; PAIN MEASUREMENT; RECOMBINANT PROTEINS;

MURINAE;

EID: 76749118433     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (125)

1. Intraplantar injection of nerve growth factor into the rat hind paw: Local edema and effects on thermal nociceptive threshold. Amann R, Schuligoi R, Herzeg G, Donnerer J PAIN 1996 64 2 323-329
2. Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice. Capsoni S, Ugolini G, Comparini A, Ruberti F, Berardi N, Cattaneo A PROC NATL ACAD SCI USA 2000 97 12 6826-6831
3. Nerve growth factor: From neurotrophin to neurokine. Levi-Montalcini R, Skaper SD, Dal Toso R, Petrelli L, Leon A TRENDS NEUROSCI 1996 19 11 514-520
4. Inflammation of the rat urinary bladder is associated with a referred thermal hyperalgesia which is nerve growth factor dependent. Jaggar SI, Scott HCF, Rice AS BR J ANAESTH 1999 83 3 442-448
5. A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. McArthur JC, Yiannoutsos C, Simpson DM, Adornato BT, Singer EJ, Hollander H, Marra C, Rubin M, Cohen BA, Tucker T, Navia BA et al NEUROLOGY 2000 54 5 1080-1088.
6. Genentech and Rinat Neuroscience announce co-development and joint commercialization agreement for anti-NGF antibody for acute and chronic pain. Genentech Inc PRESS RELEASE 2004 November 09
7. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Tuszynski MH, Thal L, Pay M, Salmon DP, U HS, Bakay R, Patel P, Blesch A, Vahlsing HL, Ho G, Tong G et al NAT MED 2005 11 5 551-555.
8. Neutralization of NGF-TrkA receptor interaction by the novel antagonistic anti-TrkA monoclonal antibody MNAC13: A structural insight. Covaceuszach S, Cattaneo A, Lamba D PROTEINS-STRUCT FUNCT BIOINFORM 2005 58 3 717-727.
9. Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization. Sevcik MA, Ghilardi JR, Peters CM, Lindsay TH, Halvorson KG, Jonas BM, Kubota K, Kuskowski MA, Boustany L, Mantyh PW PAIN 2005 115 1-2 128-141
10. Pfizer to expand neuroscience research with acquisition of biotech company Rinat Neuroscience. Pfizer Inc PRESS RELEASE 2006 April 06
11. Pfizer delivers strong second-quarter 2006 results, driven by performance of major in-line and new products. Pfizer Inc PRESS RELEASE 2006 July 20
12. BioXell and Lay Line Genomics announce license agreement for anti-TrkA antibody against pain. Lay Line Genomics SpA PRESS RELEASE 2006 February 13.
13. A humanized anti-NGF antibody with analgesic properties. Covaceuszach S, Marinelli S, Ugolini G, Pavone F, Krastanova I, Lamba D, Cattaneo A ABSTR SOC NEUROSCI 2006 36 Abs 49.13/J8.
14. The function neutralizing anti-TrkA antibody MNAC13 reduces inflammatory and neuropathic pain. Ugolini G, Marinelli S, Covaceuszach S, Cattaneo A, Pavone F PROC NATL ACAD SCI USA 2007 104 8 2985-2990
15. TrkAd5: A novel therapeutic agent for treatment of inflammatory pain and asthma. Watson JJ, Fahey MS, van den Worm E, Engels F, Nijkamp FP, Stroemer P, McMahon S, Allen SJ, Dawbarn D J PHARMACOL EXP THER 2006 316 3 1122-1129
16. Decrease in bladder overactivity with REN1820 in rats with cyclophosphamide induced cystitis. Hu VY, Zvara P, Dattilio A, Redman TL, Allen SJ, Dawbarn D, Stroemer RP, Vizzard MA J UROL 2005 173 3 1016-1021
17. Opioids in chronic non-cancer pain: Systematic review of efficacy and safety. Kalso E, Edwards JE, Moore RA, McQuay HJ PAIN 2004 112 3 372-380
18. Antibodies to nerve growth factor reverse established tactile allodynia in rodent models of neuropathic pain without tolerance. Wild KD, Bian D, Zhu D, Davis J, Bannon AW, Zhang TJ, Louis JC J PHARMACOL EXP THER 2007 322 1 282-287
19. XOMA licenses antibody technology to Pfizer. XOMA Ltd PRESS RELEASE 2007 August 28
20. NCT00545129: A study of RN624 (PF-04383119) and oxycodone in patients with pain due to cancer that has spread to bone. clinicaltrials.gov 2007 November 29
21. Amgen licenses molecule for the treatment of chronic and neuropathic pain to Ortho-McNeil-Janssen Pharmaceuticals, Inc. Amgen Inc PRESS RELEASE 2008 July 31.
22. NCT00733902: Tanezumab in osteoarthritis of the knee. clinicaltrials.gov 2008
23. Pfizer-Analyst and investor briefing American College of Rheumatology. Pfizer Inc COMPANY PRESENTATION 2008 October 28
24. XOMA receives milestone payment from Pfizer under antibody technology license. XOMA Ltd PRESS RELEASE 2009 January 22
25. Tanezumab relieves moderate to severe pain due to osteoarthritis (OA) of the knee: A phase 2 trial. Lane NE, Schnitzer TJ, Smith MD, Brown MT ARTHRITIS RHEUM 2008 58 9 Suppl S896-S897
26. Effect of anti-NGF antibodies in a rat tibia fracture model of complex regional pain syndrome type I. Sabsovich I, Wei T, Guo TZ, Zhao R, Shi X, Li X, Yeomans DC, Klyukinov M, Kingery WS, Clark JD PAIN 2008 138 1 47-60
27. Effects of a monoclonal antibody raised against nerve growth factor on skeletal pain and bone healing after fracture of the C57BL/6J mouse femur. Koewler NJ, Freeman KT, Buus RJ, Herrera MB, Jimenez-Andrade JM, Ghilardi JR, Peters CM, Sullivan LJ, Kuskowski MA, Lewis JL, Mantyh PW J BONE MINER RES 2007 22 11 1732-1742
28. RN624 (anti-NGF) improves pain and function in subjects with moderate knee osteoarthritis: A phase I study. Lane N, Webster L, Lu S, Gray M, Hefti F, Walicke P ARTHRITIS RHEUM 2005 52 9 Suppl S461
29. Increased nerve growth factor after rat plantar incision contributes to guarding behavior and heat hyperalgesia. Banik RK, Subieta AR, Wu C, Brennan TJ PAIN 2005 117 1-2 68-76
30. Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors. Abdiche YN, Malashock DS, Pons J PROTEIN SCI 2008 17 8 1326-1335
31. Novel class of pain drugs based on antagonism of NGF. Hefti FF, Rosenthal A, Walicke PA, Wyatt S, Vergara G, Shelton DL, Davies AM TRENDS PHARMACOL SCI 2006 27 2 85-91
32. Company pipeline: Pfizer. Pfizer Inc COMPANY WORLD WIDE WEB SITE 2009 March 31
33. Bradykinin and nerve growth factor release the capsaicin receptor from PtdIns(4,5)P2-mediated inhibition. Chuang HH, Prescott ED, Kong H, Shields S, Jordt SE, Basbaum AI, Chao MV, Julius D NATURE 2001 411 6840 957-962
34. Analyst presentation. BioXell SpA COMPANY PRESENTATION 2009 April 30
35. PanGenetics receives approval for clinical evaluation of anti-NGF antibody in patients with chronic pain. PanGenetics BV PRESS RELEASE 2009 June 08
36. Nerve growth factor sequestering therapy attenuates non-malignant skeletal pain following fracture. Jimenez-Andrade JM, Martin CD, Koewler NJ, Freeman KT, Sullivan LJ, Halvorson KG, Barthold CM, Peters CM, Buus RJ, Ghilardi JR, Lewis JL et al PAIN 2007 133 1-3 183-196.
37. Tanezumab, an anti-nerve growth factor (NGF) antibody, for the treatment of chronic low back pain (CLBP)-A randomized, controlled, double-blind, phase 2 trial. Katz N, Borenstein D, Birbara C, Bramson C, Nemeth M, Smith M, Brown M J PAIN 2009 10 4 Suppl Abs 268
38. PanGenetics announces acquisition by Abbott of PG110 anti-NGF antibody to treat chronic pain. PanGenetics BV PRESS RELEASE 2009 November 13
39. RN624 (anti-NGF) reduces pain and improves function in subjects with moderate to severe pain from osteoarthritis of the knee. Hefti F, Mokhtarani M, Gray M, Zhao C, Chan C J PAIN 2006 7 4 Suppl Abs 778
40. Antibody binding regions on human nerve growth factor identified by homolog-and alanine-scanning mutagenesis. Hongo JS, Laramee GR, Urfer R, Shelton DL, Restivo T, Sadick M, Galloway A, Chu H, Winslow JW HYBRIDOMA 2000 19 3 215-227
41. Efficacy and safety of PF04383119 for moderate to severe pain due to osteoarthritis (OA) of the knee: A randomized trial. Schnitzer TJ, Lane NE, Smith MD, Brown MT WORLD CONGR PAIN 2008 12 Abs PT 214
42. Efficacy and safety of PF04383119 in treating moderate to severe pain due to osteoarthritis (OA). Lane NE, Schnitzer TJ, Smith MD, Brown MT ANN RHEUM DIS 2008 67 Suppl 2 Abs THU0318
43. Preclinical safety evaluation of PF04383119 after single and multiple-dose administration in monkeys. Shelton DL, Zorbas M, Bales R, Rogers B, Pons J ANESTHESIOLOGY 2008 109 Abs A597
44. Effect of PF04383119 on post-incisional pain following iv or ip administration. Shelton DL, Vergara G, Pons J, Ho W-H, Stratton J ANESTHESIOLOGY 2008 109 Abs A1539
45. Nerve growth factor mediates hyperalgesia and cachexia in auto-immune arthritis. Shelton DL, Zeller J, Ho WH, Pons J, Rosenthal A PAIN 2005 116 1-2 8-16
46. A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone. Halvorson KG, Kubota K, Sevcik MA, Lindsay TH, Sotillo JE, Ghilardi JR, Rosol TJ, Boustany L, Shelton DL, Mantyh PW CANCER RES 2005 65 20 9426-9435
47. Effects of mouse tumor transplantation on the nervous system. Levi-Montalcini R ANN NY ACAD SCI 1952 55 2 330-342
48. The nerve growth-factor 35 years later. Levi-Montalcini R SCIENCE 1987 237 4819 1154-1162
49. Neurotrophins: Mediators and modulators of pain. Pezet S, McMahon SB ANNU REV NEUROSCI 2006 29 507-538
50. Effects of the extract of the mouse submaxillary salivary glands on the sympathetic system of mammals. Levi-Montalcini R, Cohen S ANN NY ACAD SCI 1960 85 1 324-341
51. Growth control of nerve cells by protein factor + its antiserum-Discovery of this factor may provide new leads to understanding of some neurogenetic processes. Levi-Montalcini R SCIENCE 1964 143 360 105-110
52. Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. Hinz B, Cheremina O, Brune K FASEB J 2008 22 2 383-390.
53. Current state of therapy for pain and inflammation. Abramson SB, Weaver AL ARTHRITIS RES THER 2005 7 Suppl 4 S1-S6
54. Prostanoids in nociception and pain. Zeilhofer HU BIOCHEM PHARMACOL 2007 73 2 165-174
55. Anti-inflammatory steroids induce biosynthesis of a phospholipase A2 inhibitor which prevents prostaglandin generation. Flower RJ, Blackwell GJ NATURE 1979 278 5703 456-459
56. Opioids in chronic pain. Przewlocki R, Przewlocka B EUR J PHARMACOL 2001 429 1-3 79-91
57. From the analyst's couch-The painful reality. Renfrey S, Downton C, Featherstone J NAT REV DRUG DISCOV 2003 2 3 175-176
58. Nerve growth factor: Two receptors, multiple functions. Frade JM, Barde YA BIOESSAYS 1998 20 2 137-145
59. The many faces of p75NTR. Hempstead BL CURR OPIN NEUROBIOL 2002 12 3 260-267
60. Neurotrophin signal transduction in the nervous system. Kaplan DR, Miller FD CURR OPIN NEUROBIOL 2000 10 3 381-391
61. Trk receptors: Mediators of neurotrophin action. Patapoutin A, Reichardt LF CURR OPIN NEUROBIOL 2001 11 3 272-280
62. Mechanisms of neurotrophin receptor signalling. Zampieri N, Chao MV BIOCHEM SOC TRANS 2006 34 607-611
63. Trk receptors: Roles in neuronal signal transduction. Huang EJ, Reichardt LF ANNU REV BIOCHEM 2003 72 609-642
64. Targeting nerve growth factor in pain: what is the therapeutic potential. Watson JJ, Allen SJ, Dawbarn D BIODRUGS 2008 22 6 349-359
65. Unraveling the story of NGF-mediated sensitization of nociceptive sensory neurons: On or off the Trks? Nicol GD, Vasko MR MOL INTERVENT 2007 7 1 26-41
66. Mast-cells increase in tissues of neonatal rats injected with nerve growth-factor. Aloe L, Levi-Montalcini R BRAIN RES 1977 133 2 358-366
67. Nerve growth-factor induced hyperalgesia in the neonatal and adult-rat. Lewin GR, Ritter AM, Mendell LM J NEUROSCI 1993 13 5 2136-2148
68. Peripheral and central mechanisms of NGF-induced hyperalgesia. Lewin GR, Rueff A, Mendell LM EUR J NEUROSCI 1994 6 12 1903-1912
69. NGF effects on hot plate behaviors in mice. Seta DD, De Acetis L, Aloe L, Alleva E PHARMACOL BIOCHEM BEHAV 1994 49 3 701-705
70. The effect of systemically administered recombinant human nerve growth-factor in healthy-human subjects. Petty BG, Cornblath DR, Adornato BT, Chaudhry V, Flexner C, Wachsman M, Sinicropi D, Burton LE, Peroutka SJ ANN NEUROL 1994 36 2 244-246
71. Intradermal recombinant human nerve growth factor induces pressure allodynia and lowered heat-pain threshold in humans. Dyck PJ, Peroutka S, Rask C, Burton E, Baker MK, Lehman KA, Gillen DA, Hokanson JL, OBrien PC NEUROLOGY 1997 48 2 501-505
72. Neurotrophic factors and pain. Apfel SC CLIN J PAIN 2000 16 2 7-11
73. Nerve growth factor for the treatment of diabetic neuropathy: What went wrong, what went right, and what does the future hold? Apfel SC INT REV NEUROBIOL 2002 50 393-413
74. Injection of nerve growth factor into human masseter muscle evokes longlasting mechanical allodynia and hyperalgesia. Svensson P, Cairns BE, Wang K, Arendt-Nielsen L PAIN 2003 104 1-2 241-247
75. Mutations in the TrkA/NGF receptor gene in patients with congenital insensitivity to pain with anhidrosis. Indo Y, Tsuruta M, Hayashida Y, Karim MA, Ohta K, Kawano T, Mitsubuchi H, Tonoki H, Awaya Y, Matsuda I NAT GENET 1996 13 4 485-488
76. Congenital insensitivity to pain with anhidrosis (CIPA): Novel mutations of the TrkA (NTRK1) gene, a putative uniparental disomy, and a linkage of the mutant TrkA and PKLR genes in a family with CIPA and pyruvate kinase deficiency. Indo Y, Mardy S, Miura Y, Moosa A, Ismail EAR, Toscano E, Andria G, Pavone V, Brown DL, Brooks A, Endo F et al HUM MUTAT 2001 18 4 308-318
77. Molecular basis of congenital insensitivity to pain with anhidrosis (CIPA): Mutations and polymorphisms in TrkA (NTRK1) gene encoding the receptor tyrosine kinase for nerve growth factor. Indo Y HUM MUTAT 2001 18 6 462-471 (Pubitemid 33131549)
78. A mutation in the nerve growth factor ß gene (NGFß) causes loss of pain perception. Einarsdottir E, Carlsson A, Minde J, Toolanen G, Svensson O, Solders G, Holmgren G, Holmberg D, Holmberg M HUM MOL GENET 2004 13 8 799-805
79. Human cholinergic basal forebrain: Chemoanatomy and neurologic dysfunction. Mufson EJ, Ginsberg SD, Ikonomovic MD, DeKosky ST J CHEM NEUROANAT 2003 26 4 233-242
80. Loss of nucleus basalis neurons containing TrkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer's disease. Mufson EJ, Ma SY, Cochran EJ, Bennett DA, Beckett LA, Jaffar S, Saragovi HU, Kordower JH J COMP NEUROL 2000 427 1 19-30
81. Differential-effects on sensory nerve processes and behavioral alterations in the rat after treatment with antibodies to nerve growth-factor. Urschel BA, Brown PN, Hulsebosch CE EXP NEUROL 1991 114 1 44-52.
82. Nerve growth-factor contributes to the generation of inflammatory sensory hypersensitivity. Woolf CJ, Safieh-Garabedian B, Ma QP, Crilly P, Winter J NEUROSCIENCE 1994 62 2 327-331
83. Effect of NGF and anti-NGF on neuropathic pain in rats following chronic constriction injury of the sciatic nerve. Ro LS, Chen ST, Tang LM, Jacobs JM PAIN 1999 79 2-3 265-274
84. Attenuation of mechanical hyperalgesia following spinal cord injury by administration of antibodies to nerve growth factor in the rat. Gwak YS, Nam TS, Paik KS, Hulsebosch CE, Leem JW NEUROSCI LETT 2003 336 2 117-120
85. Role of nerve growth factor in the trinitrobenzene sulfonic acid-induced colonic hypersensitivity. Delafoy L, Raymond F, Doherty AM, Eschalier A, Diop L PAIN 2003 105 3 489-497
86. Nerve growth factor and gastric hyperalgesia in the rat. Lamb K, Kang YM, Gebhart GF, Bielefeldt K NEUROGASTROENTEROL MOTIL 2003 15 4 355-361
87. The biological effects of endogenous nerve growth factor on adult sensory neurons revealed by a TrkA-IgG fusion molecule. McMahon SB, Bennett DL, Priestley JV, Shelton DL NAT MED 1995 1 8 774-780
88. Effect of blockade of nerve growth factor and tumor necrosis factor on pain behaviors after plantar incision. Zahn PK, Subieta A, Park SS, Brennan TJ J PAIN 2004 5 3 157-163
89. Nerve growth-factor binds to normal human keratinocytes through high and low-affinity receptors and stimulates their growth by a novel autocrine loop. Di Marco E, Mathor M, Bondanza S, Cutuli N, Marchisio PC, Cancedda R, Deluca M J BIOL CHEM 1993 268 30 22838-22846
90. Functional blockade of tyrosine kinase a in the rat basal forebrain by a novel antagonistic anti-receptor monoclonal antibody. Cattaneo A, Capsoni S, Margotti E, Righi M, Kontsekova E, Pavlik P, Filipcik P, Novak M J NEUROSCI 1999 19 22 9687-9697
91. Dissecting NGF interactions with TrkA and p75 receptors by structural and functional studies of an anti-NGF neutralizing antibody. Covaceuszach S, Cassetta A, Konarev PV, Gonfloni S, Rudolph R, Svergun DI, Lamba D, Cattaneo A J MOL BIOL 2008 381 4 881-896
92. Three distinct types of monoclonal-antibodies after longterm immunization of rats with mouse nerve growth-factor. Cattaneo A, Rapposelli B, Calissano P J NEUROCHEM 1988 50 4 1003-1010
93. Towards non invasive nerve growth factor therapies for Alzheimer's disease. Cattaneo A, Capsoni S, Paoletti F J ALZHEIMER DIS 2008 15 2 255-283
94. Amyloid plaques in a model for sporadic Alzheimer's disease based on transgenic anti-nerve growth factor antibodies. Capsoni S, Giannotta S, Cattaneo A MOL CELL NEUROSCI 2002 21 1 15-28
95. Delivery of NGF to the brain: Intranasal versus ocular administration in anti-NGF transgenic mice. Capsoni S, Covaceuszach S, Ugolini G, Spirito F, Vignone D, Stefanini B, Amato G, Cattaneo A J ALZHEIMER DIS 2009 16 2 371-388
96. Early inflammation and immune response mRNAs in the brain of AD11 anti-NGF mice. D'Onofrio M, Arisi I, Brandi R, Di Mambro A, Felsani A, Capsoni S, Cattaneo A NEUROBIOL AGING 2009 doi:10.1016/j.neurobiolaging.2009.05.023
97. Brain to plasma amyloid-ß efflux: A measure of brain amyloid burden in a mouse model of Alzheimer's disease. DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM SCIENCE 2002 295 5563 2264-2267
98. Nerve growth factor is an autocrine survival factor for memory B lymphocytes. Torcia M, BracciLaudiero L, Lucibello M, Nencioni L, Labardi D, Rubartelli A, Cozzolino F, Aloe L, Garaci E CELL 1996 85 3 345-356 (Pubitemid 26160706)
99. Osteoarthritis-An untreatable disease? Wieland HA, Michaelis M, Kirschbaum BJ, Rudolphi KA NAT REV DRUG DISCOV 2005 4 4 331-344
100. Osteoarthritic pain: A review of current, theoretical and emerging therapeutics Read SJ, Dray A EXPERT OPIN INVEST DRUGS 2008 17 5 619-640
101. The post-NSAID era: What to use now for the pharmacologic treatment of pain and inflammation in osteoarthritis. Scanzello CR, Moskowitz NK, Gibofsky A CURR RHEUMATOL REP 2008 10 1 49-56
102. Treating skeletal pain: Limitations of conventional antiinflammatory drugs, and anti-neurotrophic factor as a possible alternative. Xian CJ, Zhou XF NAT CLIN PRACT RHEUMATOL 2009 5 2 92-98
103. TrkA alternative splicing: A regulated tumor-promoting switch in human neuroblastoma. Tacconelli A, Farina AR, Cappabianca L, DeSantis G, Tessitore A, Vetuschi A, Sferra R, Rucci N, Argenti B, Screpanti I, Gulino A et al CANCER CELL (ONLINE) 2004 6 4 347-360
104. Nerve growth factor is a potential therapeutic target in breast cancer. Adriaenssens E, Vanhecke E, Saule P, Mougel A, Page A, Romon R, Nurcombe V, Le Bourhis X, Hondermarck H CANCER RES 2008 68 2 346-351
105. Peptibodies: The new cool technology. Sutherland S DRUG DISC TODAY 2004 9 16 683-683
106. Small peptide mimics of nerve growth factor bind TrkA receptors and affect biological responses. LeSauteur L, Wei L, Gibbs BF, Saragovi HU J BIOL CHEM 1995 270 12 6564-6569
107. Protein therapeutics: A summary and pharmacological classification. Leader B, Baca QJ, Golan DE NAT REV DRUG DISCOV 2008 7 1 21-39
108. Monoclonal antibodies market. Reichert J, Pavlou A NAT REV DRUG DISCOV 2004 3 5 383-384
109. Monoclonal antibodies as innovative therapeutics. Reichert JM CURR PHARM BIOTECHNOL 2008 9 6 423-430
110. Monoclonal antibody successes in the clinic. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC NAT BIOTECHNOL 2005 23 9 1073-1078
111. NGF, an old molecule with new functions and new therapeutic applications. Hefti FF COMPANY PRESENTATION 2006
112. Alteration of neurotrophins in the hippocampus and cerebral cortex of young rats exposed to chlorpyrifos and methyl parathion. Betancourt AM, Filipov NM, Carr RL TOXICOL SCI 2007 100 2 445-455.
113. Targeting of neurotrophic factors, their receptors, and signaling pathways in the developmental neurotoxicity of organophosphates in vivo and in vitro. Slotkin TA, Seidler FJ, Fumagalli F BRAIN RES BULL 2008 76 4 424-438
114. Glucocorticoids and the hippocampus. developmental interactions facilitating the expression of behavioral inhibition. Takahashi LK MOL NEUROBIOL 1996 13 3 213-226
115. Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Lazar-Molnar E, Hegyesi H, Toth S, Falus A CYTOKINE 2000 12 6 547-554
116. Expression of growth factors and growth factor receptors in normal and tumorous human thyroid tissues. van der Laan BF, Freeman JL, Asa SL THYROID 1995 5 1 67-73
117. Novel localization of low affinity NGF receptor (p75) in the stroma of prostate cancer and possible implication in neoplastic invasion: An immunohistochemical and ultracytochemical study. Rende M, Rambotti MG, Stabile AM, Pistilli A, Montagnoli C, Chiarelli MT, Mearini E PROSTATE 2009 doi:10.1002/pros.21089
118. Expression of nerve growth factor and tyrosine kinase receptor A and correlation with perineural invasion in pancreatic cancer. Ma J, Jiang Y, Jiang Y, Sun Y, Zhao X J GASTROENTEROL HEPATOL 2008 23 12 1852-1859
119. Identification of the neurotrophin receptors p75 and Trk in a series of Wilms' tumors. Donovan MJ, Hempstead B, Huber LJ, Kaplan D, Tsoulfas P, Chao M, Parada L, Schofield D AM J PATHOL 1994 145 4 792-801
120. Peripheral anti-Aß antibody alters CNS and plasma Aß clearance and decreases brain Aß burden in a mouse model of Alzheimer's disease. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM PROC NATL ACAD SCI USA 2001 98 15 8850-8855
121. NGF blocking antibody in treating moderate to severe pain due to osteoarthritis. Lin JC IBC ANN CONF ANTIBODY 2008 9
122. Pain in Europe: A report. PainEurope.com COMPANY PUBLICATION 2004
123. Pfizer at the 27th Annual JP Morgan Healthcare Conference. Mackay M JP MORGAN 2009 January 13
124. Letter from the Editor. Shi L TRENDS BIO/PHARMACEUTICAL INDUSTRY 2008 4 2 2
125. Peripheral neutralization of nerve growth factor induces immunosympathectomy and central neurodegeneration in transgenic mice. Capsoni S, Tiveron C, Amato G, Vignone D, Cattaneo A J ALZHEIMER DIS 2010 In press